Nereus Pharmaceuticals is an innovative drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize novel biologically active compounds, the Company's two oncology drug candidates are potentially best-in-class small molecules. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated in a Phase 2 trial for non-small cell lung carcinoma and a proteasome inhibitor NPI-0052 is being evaluated in multiple Phase I trials for solid tumors, lymphomas and multiple myeloma. Nereus' discovery portfolio also includes additional drug candidates for oncology, inflammation and infectious diseases.